Antiviral favipiravir used for the treatment of COVID-19 steered Glenmark Pharmaceuticals Limited to a “landmark” fiscal first quarter ended 30 June 2021 on home turf, while new launches such as generic Brovana (arformoterol tartrate) in the US appear promisingly poised as well.
Glenmark’s favipiravir product Fabiflu, which has had a sterling run in India over the recent past, raked in sales of INR3.50bn ($47
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?